Quantification of Free Circulating Tumor DNA as a Diagnostic Marker for Breast Cancer
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
AIM: To determine whether the amounts of circulating DNA could discriminate between breast cancer patients and healthy individuals by using real-time PCR quantification methodology. METHODS: Our standard protocol for quantification of cell-free plasma DNA involved 175 consecutive patients with breast cancer and 80 healthy controls. RESULTS: We found increased levels of circulating DNA in breast cancer patients compared to control individuals (105.2 vs. 77.06 ng/mL, p < 0.001). We also found statistically significant differences in circulating DNA amounts in patients before and after breast surgery (105.2 vs. 59.0 ng/mL, p = 0.001). Increased plasma cell-free DNA concentration was a strong risk factor for breast cancer, conferring an increased risk for the presence of this disease (OR, 12.32; 95% CI, 2.09-52.28; p < 0.001). CONCLUSIONS: Quantification of circulating DNA by real-time PCR may be a good and simple tool for detection of breast cancer with a potential to clinical applicability together with other current methods used for monitoring the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection and quantification of mutations in the plasma of patients with colorectal tumors
Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., Diaz, L. A., Goodman, S. N., David, K. A., Juhl, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507904102 · Cited by 1,188
Circulating nucleic acids (CNAs) and cancer—A survey
Fleischhacker, M., & Schmidt, B. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.10.001 · Cited by 851
Cited by
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
Fragment Length of Circulating Tumor DNA
Underhill, H. R., Kitzman, J. O., Hellwig, S., Welker, N. C., Daza, R., Baker, D. N., Gligorich, K. M., Rostomily, R. C., Bronner, M. P., & Shendure, J. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006162 · Cited by 671
Current and emerging biomarkers in breast cancer: prognosis and prediction
Weigel, M. T., & Dowsett, M. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-10-0136 · Cited by 496
Breast cancer diagnosis: Imaging techniques and biochemical markers
Jafari, S. H., Saadatpour, Z., Salmaninejad, A., Momeni, F., Mokhtari, M., Nahand, J. S., Rahmati, M., Mirzaei, H., & Kianmehr, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26379 · Cited by 410
Cell-free DNA in the blood as a solid tumor biomarker–a critical appraisal of the literature
Jung, K., Fleischhacker, M., & Rabien, A. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.07.032 · Cited by 337
Kohler, C., Radpour, R., Barekati, Z., Asadollahi, R., Bitzer, J., Wight, E., Bürki, N., Diesch, C., Holzgreve, W., & Zhong, X. Y. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-105 · Cited by 215
“The ccf tumor DNA detection seems to be more reliable for predicting relapse than the standard biomarker, carcinoembryonic antigen (CEA), used for the management of colorectal cancer [22].”
Omics Technologies Improving Breast Cancer Research and Diagnostics
Orsini, A., Diquigiovanni, C., & Bonora, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612690 · Cited by 52
Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas
Tsoi, K. M., Gokgoz, N., Darville-O'Quinn, P., Prochazka, P., Malekoltojari, A., Griffin, A. M., Ferguson, P. C., Wunder, J. S., & Andrulis, I. L. (2021) · Bone & Joint Research · doi:10.1302/2046-3758.109.bjr-2021-0014.r1 · Cited by 17
Metadata
- Authors
- Catarino, R., Ferreira, M. M., Rodrigues, H., Coelho, A., Nogal, A., Sousa, A., & Medeiros, R.
- Venue
- DNA and Cell Biology
- Publisher
- SAGE Publications
- Published
- 2008-08
- Volume
- 27
- Issue
- 8
- Pages
- 415-421
- ISSN
- 1044-5498 (ISSN-L)
- 1557-7430
- OpenAlex
- W2050002587
- Cited by
- 111
- References
- 2
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.